linjc16/ctgov huggingface dataset:
CyPass Clinical Experience Study

Study Overview
=================
Brief Summary
-----------------
This study is to evaluate the long-term safety, effectiveness and clinical experience of the CyPass Micro-Stent in patients with glaucoma.

Official Title
-----------------
A Multicenter Registry Study to Capture Data With Respect to CyPass Clinical Experience

Conditions
-----------------
Open Angle Glaucoma (OAG)

Intervention / Treatment
-----------------
* Device: CyPass Micro-Stent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of OAG IOP ≥ 21 mmHg and ≤ 31 mmHg (with or without ocular hypotensive medication) Exclusion Criteria: Acute angle closure, narrow angle, uveitic or neovascular glaucoma Normal tension glaucoma
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CyPass Micro-stent<br>Patients in whom CyPass Micro-stent implantation was attempted. | Device: CyPass Micro-Stent<br>* The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of they eye.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of intraoperative and postoperative adverse events |  | Day 0 - Year 3 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraocular pressure (IOP) reduction |  | 1 - 36 months postoperatively | 
| Ocular hypotensive medication use |  | 1 - 36 months postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glaucoma, Glaucoma device, Glaucoma surgery, Intraocular pressure
Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites

Study Overview
=================
Brief Summary
-----------------
Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites

Detailed Description
-----------------
To detect accuracy of MDCT in differentiation between different types of ascites and its underlying cause . To evaluate the diagnostic accuracy of measuring the CT density of the ascitic fluid (in Housefield units) to differentiate between different types of ascites in comparison to aspiration cytology results.

Official Title
-----------------
Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites

Conditions
-----------------
Ascites

Intervention / Treatment
-----------------
* Device: Detection of ascites using CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who are diagnosed with ascites by clinical examination or by any other investigations such as ultrasound. Exclusion Criteria: Patient with bleeding tendancy and on anticoagulant drugs.- Patients who are pregnant .
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Detection of ascites using CT|Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| differentiate between different types of ascites and its underlying cause | differentiate between different types of ascites and its underlying causes by measuring the CT density of the ascitic fluid (in Hounsfield units) | 2022 |
Comparison of Deviation Types Among Astigmatic Children With Or Without Amblyopia

Study Overview
=================
Brief Summary
-----------------
the records of astigmatic children were reviewed and any deviation was investigated at near and distance. refractive errors, stereopsis, convergence insufficiency were also evaluated. children were divided into two groups according to the presence of amblyopia and ocular deviations and other parameters were compared between groups.

Detailed Description
-----------------
The aim of the study was to evaluate deviations in children with ≥1,75 diopter (D) astigmatism with or without amblyopia. The records of children with ≥1,75 D astigmatism were investigated. Subjects with and without amblyopia composed group 1 and 2, respectively. The mean age, gender, amount and type of deviation, presence of convergence insufficiency (CI), stereopsis, time of initial spectacle use and follow-up time, differences in best corrected visual acuity (VoD) and spherical equivalent (SE) between eyes were noted and compared between the groups. Best corrected visual acuity (BCVA), mean SE, astigmatism measurements were also noted and compared between amblyopic, fellow and non-amblyopic eyes.

Official Title
-----------------
Associated Professor, Director of Strabismus Department

Conditions
-----------------
Astigmatism of Both Eyes, Amblyopia, Strabismus

Intervention / Treatment
-----------------
* Other: ophthalmic examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: astigmatisma ≥1,75 Diopter Exclusion Criteria: systemic diseases additional ocular diseases neurological diseases

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1, astigmatic patients with amblyopia<br>astigmatic children with amblyopia | Other: ophthalmic examination<br>* ophthalmic examination including; best corrected visual acuity, alternating prism cover test, retinoscopy, fundus examination, ocular vergence evaluation<br>|
| Group 2, astigmatic patients without amblyopia<br>astigmatic children without amblyopia | Other: ophthalmic examination<br>* ophthalmic examination including; best corrected visual acuity, alternating prism cover test, retinoscopy, fundus examination, ocular vergence evaluation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ocular deviation | ocular deviation measured by alternate prism cover test, prism diopter | 24 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| convergence | presence of convergence insufficiency at 10 cm far from visual axe. | 24 month |
Passive Smoking and LL-37 in Children

Study Overview
=================
Brief Summary
-----------------
This study investigates the salivary LL-37 in passive smoking-exposed and unexposed children and the association between salivary LL-37 levels and periodontal clinical parameters in these children.Unstimulated salivary samples were collected from 180 children (90 passive smoking-exposed and 90 passive smoking-unexposed)

Detailed Description
-----------------
Diverse mechanisms conduce to the detrimental periodontal effects of passive smoking, including alteration of both microbial and host response factors. Antimicrobial peptides are considered to be an important intermediate step in initiating an initial immune response against the microbial side of the oral gingival epithelium and in the transition to acquired immunity. LL-37 has a wide antimicrobial activity against both cariogenic and periopathogenic bacteria and its role in maintaining oral health has recently been stated

Official Title
-----------------
Salivary LL-37 and Periodontal Health in Children Exposed to Passive Smoking

Conditions
-----------------
Innate Immunity, Periodontal Health

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Systemically healthy children Exclusion Criteria: Any medications known to affect defense system and periodontium The presence of orthodontic / intraoral appliance

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Passive smoking-exposed children<br>This group consists of children whose family members have smoked at home since the birth of the child. | |
| Passive smoking-unexposed children<br>This group consists of children whose family members have not smoked at home since the birth of the child. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antimicrobial Peptide | LL-37 (pg/mL) | In the first 18 months of study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Passive smoking measurement | Cotinine (ng/mL) | In the first 18 months of study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Children, Cotinine, LL-37, Passive smoking, Periodontal health, Saliva
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)

Study Overview
=================
Brief Summary
-----------------
A multicenter trial to assess the safety and efficacy of an investigational drug in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with confirmed solid tumors who will be treated with a chemotherapy regimen that includes cisplatin. The study will evaluate the investigational drug for the treatment of CINV during the first cycle of treatment with cisplatin.

Official Title
-----------------
A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Safety, Tolerability and Efficacy of Aprepitant Regimen Compared to Ondansetron Regimen for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With High Dose Cisplatin in Cycle 1

Conditions
-----------------
Nausea, Vomiting

Intervention / Treatment
-----------------
* Drug: MK0869, aprepitant / Duration of Treatment: 3 days
* Drug: Comparator: ondansetron / Duration of Treatment: 4 days


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is greater than 18 years of age. Patient is scheduled to receive his/her first course of cisplatin chemotherapy for a solid tumor. Patient has a prognosis (life expectancy) greater than or equal to 3 months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0869, aprepitant / Duration of Treatment: 3 days|nan|
|Drug: Comparator: ondansetron / Duration of Treatment: 4 days|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient vomiting |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of rescue therapies |  |  |
Bergonie Institute Breast Cancer Database

Study Overview
=================
Brief Summary
-----------------
A database of breast cancer patients was established at Institute Bergonié since the 90s , to assess patients' survival, assess practice, search for prognostic factors.

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Breast cancer Aged 18 years and over First treatment at Bergonie Institute Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Survival |  | 5 years | 
| Overall Survival |  | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distant disease-free survival | D-DFS, distant disease-free survival, as defined following DATECAN guidelines (Gourgou et al. Annals Oncol 2015). D-DFS is defined as the time to death or appearance/occurrence of metastases/distant recurrence, whichever occurs first | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
breast cancer, survival, prognosis factors
Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) Patient

Study Overview
=================
Brief Summary
-----------------
The goal of this project is to determine whether this device is a practical and realistic means for ALS patients to operate their computers with only the use of facial, brainwave, and eye movements. This study is intended to evaluate both the complexity of the system and the degree to which complications of ALS (such as severity of involuntary movements) may interfere with the use of cyberlink.

Official Title
-----------------
Assessment of the Cyberlink Control System for Use by the ALS Patient

Conditions
-----------------
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Those aged 18-75 diagnosed with probable or definite ALS. Exclusion Criteria: Those with decision impairment will not be considered.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ALS<br>Subjects having either definite or probable ALS by El Escorial Criteria. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Usability of the Cyberlink System | Reliability and accuracy of the Cyberlink System at the end of the 4th session will be used to assess overall usability of the system | 4 1-hr sessions | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Amyotrophic Lateral Sclerosis, Cerebrospinal Fluid, Neurodegenerative Disease, Motor Neuron Disease, Autonomic Nervous System, Neurodegenerative Diseases, Movement Disorders
Effects of Serotonin Inhibitors on Patient-controlled Analgesia Related Nausea and Vomiting

Study Overview
=================
Brief Summary
-----------------
ED50 of dexmedetomidine for prevention of emergence agitation after tonsillectomy or adenoidectomy in children

Conditions
-----------------
Agitation

Intervention / Treatment
-----------------
* Behavioral: agitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: tonsillectomy or adenoidectomy Exclusion Criteria: development delay, CNS abnormality

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: agitation|agitation score after desflurane anesthesia|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| agitation score | agitation score | 30 minutes after postoperatuib | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
agitation, desflurane, children
Electrical Stimulation During Immobilization

Study Overview
=================
Brief Summary
-----------------
In the present study, the effects of 5 days of lower limb immobilization with or without daily neuromuscular electrical stimulation on muscle mass and muscle fiber characteristics will be determined.

Official Title
-----------------
The Effects of Daily Neuromuscular Electrical Stimulation on Muscle Mass During Short-term One-legged Knee Immobilization in Healthy Young Men

Conditions
-----------------
Disuse Atrophy, Immobilization, Neuromuscular Electrical Stimulation

Intervention / Treatment
-----------------
* Behavioral: immobilization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male Aged from 18-35 years 18.5 < BMI < 30 kg/m2 Exclusion Criteria: Smoking Performing regular resistance training in the previous 6 months Hypertension (according to WHO criteria) [46] and/or cardiovascular disease Any back/leg/knee/shoulder complaints which may interfere with the use of crutches Use of any prescribed medication Type 2 diabetes mellitus Any family history of thrombosis All co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthritis, spasticity/rigidity, all neurological disorders and paralysis). Myocardial infarction within the last 3 years Use of anti-coagulants

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Immobilization with NMES<br>Immobilization with daily NMES | Behavioral: immobilization<br> <br> |
| Placebo Comparator: Immobilization without NMES<br>Immobilization without daily NMES | Behavioral: immobilization<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| muscle mass, muscle fiber size |  | three days before immobilization, and directly after immobilization (day of cast removal; day 6) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| muscle strength measured by quadriceps 1-Repetition Maximum by Leg Extension |  | three days before immobilization, and directly after immobilization (day of cast removal; day 6) |
PSYCHOLOGICAL CARE AND HYPNOSIS IN PATIENTS WITH CANCER

Study Overview
=================
Brief Summary
-----------------
The general aim of the research that we propose to implement is to study the potential benefits of hypnosis in the psycho-social care of patients with cancer. The main goal of this study is to measure the effects of hypnosis sessions on quality of life, anxiety and patient adjustment strategies. The effects of these interventions will be the subject of quantitative measurement via standardized scales in pre- and post-intervention situations of the potential effects of hypno-therapeutic intervention in cancer patients and

Official Title
-----------------
PSYCHOLOGICAL CARE AND HYPNOSIS IN PATIENTS WITH CANCER

Conditions
-----------------
Hypnosis and Cancer

Intervention / Treatment
-----------------
* Other: hypnosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with any kind of cancer and followed by a psychologist Exclusion Criteria: Patient with neurological trouble Patient with psychiatric decompassation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patient ongoing hypnosis sessions<br> | Other: hypnosis<br>* patient with cancer will undergo sessions of hypnosis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| quality of life scale | QLQC30 assessment | 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| anxiety scales | Edmonton Symptom Assessment System | 36 months |
Echocardiography in Patients With Covid-19

Study Overview
=================
Brief Summary
-----------------
Prospective observational study of patients treated due to Covid-19 disease. Observation and analysis of echocardiographic studies performed in the intensive care setting.

Official Title
-----------------
Echocardiography in Patients With Covid-19 Undergoing Intensive Care Therapy

Conditions
-----------------
COVID, ARDS, Human

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age above 18 years Covid-19 disease invasive Ventilation Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ICU Mortality |  | up to 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ICU length-of stay |  | up to 90 days | 
| ICU ventilator free days |  | up to 90 days | 
| Hospital length-of-stay |  | up to 90 days |